Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00534209 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Patients With Stages IIIB/IV Non-Small Cell Lung Cancer Who Have Finished First-Line Chemotherapy
A Phase 1 study, sponsored by University of Miami.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00534209 is a Phase 1 study that was terminated before completion, run by University of Miami. The registered enrollment target is 1 participants.
The verdict
NCT00534209, a Phase 1 study, was terminated before completion, sponsored by University of Miami.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an immune response to kill tumor cells. PURPOSE: This randomized phase I/II trial is studying the side effects of vaccine therapy and to see how well it works in treating patients with stage IIIB or stage IV non-small cell lung cancer who have finished first-line chemotherapy.
Interventions
- OTHER Placebo
- BIOLOGICAL Allogeneic B7.1/HLA-A1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2009-01 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00534209
The ClinicalTrials.gov registry entry for NCT00534209 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00534209 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00534209 about?
NCT00534209 is a clinical study titled "Vaccine Therapy in Patients With Stages IIIB/IV Non-Small Cell Lung Cancer Who Have Finished First-Line Chemotherapy". RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an immune response to kill tumor cells. PURPOSE: This randomized phase I/II trial is studying the side effects of vaccine therapy and to see how well it works in treating patients with stage IIIB or stage IV non-small c...
What is the current status of trial NCT00534209?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2009-01. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00534209?
The interventions under investigation include: Placebo (OTHER), Allogeneic B7.1/HLA-A1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00534209?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.